Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine
- PMID: 2880861
- DOI: 10.1210/jcem-64-3-447
Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine
Abstract
We studied the effects of acute and chronic sc administration of SMS 201-995 (SMS), a long-acting somatostatin analog, in acromegalic patients. The results were compared with those obtained in the same patients treated with oral bromocriptine (Brc). A single dose of 50 micrograms SMS administered to 28 patients induced a more rapid, greater, and more prolonged reduction in plasma GH levels than did 2.5 mg Brc. Chronic treatment [60-330 days; mean 208 +/- 23 (+/- SEM)] with SMS (100-300 micrograms/day) induced in 16 patients a significantly greater decrease in mean plasma GH and somatomedin-C levels than did 20 mg Brc. Combined treatment with the 2 agents had an additional effect. The clinical and metabolic parameters of acromegaly dramatically improved in all patients whose plasma GH and somatomedin-C levels decreased even if they were not normalized by SMS. Reduction in tumor size occurred in 3 of the 10 patients examined by computed tomography before and during SMS treatment. We conclude that SMS is more effective than Brc and that the 2 drugs may be complementary in the medical treatment of acromegaly.
Similar articles
-
A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.J Clin Endocrinol Metab. 1986 Jul;63(1):16-9. doi: 10.1210/jcem-63-1-16. J Clin Endocrinol Metab. 1986. PMID: 2872225
-
Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.J Clin Endocrinol Metab. 1986 Dec;63(6):1348-53. doi: 10.1210/jcem-63-6-1348. J Clin Endocrinol Metab. 1986. PMID: 2878007
-
Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.J Clin Endocrinol Metab. 1988 Jan;66(1):16-23. doi: 10.1210/jcem-66-1-16. J Clin Endocrinol Metab. 1988. PMID: 2891720
-
The role of somatostatin agonistic analogs in the treatment of acromegaly.Metabolism. 1996 Aug;45(8 Suppl 1):109-10. doi: 10.1016/s0026-0495(96)90100-6. Metabolism. 1996. PMID: 8769400 Review.
-
Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitary testing: a review of the literature on 36 cases of pituitary carcinoma.Am J Med Sci. 1989 Aug;298(2):109-18. doi: 10.1097/00000441-198908000-00007. Am J Med Sci. 1989. PMID: 2669475 Review.
Cited by
-
Meta-analysis on the effects of octreotide on tumor mass in acromegaly.PLoS One. 2012;7(5):e36411. doi: 10.1371/journal.pone.0036411. Epub 2012 May 4. PLoS One. 2012. PMID: 22574156 Free PMC article.
-
Medical management of growth hormone-secreting pituitary adenomas.Pituitary. 2002;5(2):67-76. doi: 10.1023/a:1022356313153. Pituitary. 2002. PMID: 12675503 Review.
-
Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion.Klin Wochenschr. 1991 Jan 22;69(2):83-90. doi: 10.1007/BF01666821. Klin Wochenschr. 1991. PMID: 1902881
-
Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.Pituitary. 1999;1(2):115-20. doi: 10.1023/a:1009932521242. Pituitary. 1999. PMID: 11081189
-
Current status and future opportunities for controlling acromegaly.Pituitary. 2002;5(3):185-96. doi: 10.1023/a:1023369317275. Pituitary. 2002. PMID: 12812311 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources